SG10201708048XA - Humanized anti-cd134 (ox40) antibodies and uses thereof - Google Patents

Humanized anti-cd134 (ox40) antibodies and uses thereof

Info

Publication number
SG10201708048XA
SG10201708048XA SG10201708048XA SG10201708048XA SG10201708048XA SG 10201708048X A SG10201708048X A SG 10201708048XA SG 10201708048X A SG10201708048X A SG 10201708048XA SG 10201708048X A SG10201708048X A SG 10201708048XA SG 10201708048X A SG10201708048X A SG 10201708048XA
Authority
SG
Singapore
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
SG10201708048XA
Inventor
Petrus Johannes Simons
Louis Boon
Jinquan Luo
Randall Brezski
Monica Goldberg
Original Assignee
Biocerox Prod Bv
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891522&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201708048X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocerox Prod Bv, Janssen Pharmaceuticals Inc filed Critical Biocerox Prod Bv
Publication of SG10201708048XA publication Critical patent/SG10201708048XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG10201708048XA 2013-03-18 2014-03-18 Humanized anti-cd134 (ox40) antibodies and uses thereof SG10201708048XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13159794 2013-03-18

Publications (1)

Publication Number Publication Date
SG10201708048XA true SG10201708048XA (en) 2017-10-30

Family

ID=47891522

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201708048XA SG10201708048XA (en) 2013-03-18 2014-03-18 Humanized anti-cd134 (ox40) antibodies and uses thereof
SG11201507781VA SG11201507781VA (en) 2013-03-18 2014-03-18 Humanized anti-cd134 (ox40) antibodies and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201507781VA SG11201507781VA (en) 2013-03-18 2014-03-18 Humanized anti-cd134 (ox40) antibodies and uses thereof

Country Status (32)

Country Link
US (3) US9790281B2 (en)
EP (2) EP2976361B1 (en)
JP (1) JP2016515544A (en)
KR (1) KR20160006168A (en)
CN (1) CN105229032A (en)
AU (2) AU2014238546C1 (en)
BR (1) BR112015023862A2 (en)
CA (1) CA2907436A1 (en)
CL (2) CL2015002793A1 (en)
CR (1) CR20150498A (en)
CY (1) CY1120752T1 (en)
DK (1) DK2976361T3 (en)
EA (1) EA201591495A1 (en)
ES (1) ES2687282T3 (en)
HK (1) HK1215035A1 (en)
HR (1) HRP20181478T1 (en)
HU (1) HUE040234T2 (en)
IL (1) IL241701A0 (en)
LT (1) LT2976361T (en)
MD (2) MD20180107A2 (en)
MX (2) MX2015013288A (en)
NZ (1) NZ712903A (en)
PE (1) PE20160690A1 (en)
PH (1) PH12015502185A1 (en)
PL (1) PL2976361T3 (en)
PT (1) PT2976361T (en)
RS (1) RS57840B1 (en)
SG (2) SG10201708048XA (en)
SI (1) SI2976361T1 (en)
UA (1) UA119319C2 (en)
WO (1) WO2014148895A1 (en)
ZA (1) ZA201507021B (en)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EP2972348B1 (en) 2013-03-14 2018-08-15 The Board of Trustees of The Leland Stanford Junior University Methods of detecting donor-specific antibodies
BR112015023862A2 (en) 2013-03-18 2017-10-24 Biocerox Prod Bv isolated antibody, isolated nucleic acid molecule, vector, host cell, method of enhancing an immune response, method of treating cancer, pharmaceutical composition, and isolated agonistic antibody
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
TW201619200A (en) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
CN107109484B (en) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment
CN106796235B (en) 2014-11-03 2021-01-29 豪夫迈·罗氏有限公司 Assays for detecting T cell immune subsets and methods of use thereof
CN107073126A (en) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and TIGIT inhibitor
BR112017010198A2 (en) 2014-11-17 2017-12-26 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US10457735B2 (en) * 2015-01-08 2019-10-29 BioNTech SE Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains
MX2017011194A (en) 2015-03-03 2018-04-10 Kymab Ltd Antibodies, uses & methods.
MX2017012805A (en) 2015-04-07 2018-04-11 Genentech Inc Antigen binding complex having agonistic activity and methods of use.
BR112017022994A2 (en) * 2015-04-28 2019-11-19 Mitsubishi Tanabe Pharma Corp rgma binding protein and use thereof
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
LT3303396T (en) * 2015-05-29 2023-01-10 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
PE20240096A1 (en) 2015-10-02 2024-01-18 Hoffmann La Roche BISPECIFIC ANTIBODIES SPECIFIC FOR A CO-STIMULATORY TNF RECEPTOR
WO2017063162A1 (en) * 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 Anti-ox40 antibody and application thereof
CN108472382A (en) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 Anti- factor D antibody variants conjugate and application thereof
JP2019500892A (en) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Antibodies that specifically bind to TIM-3 and uses thereof
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
US10527613B2 (en) * 2015-11-10 2020-01-07 The Board Of Trustees Of The Leland Stanford Junior University Biomarker detection methods and systems and kits for practicing same
KR20180083944A (en) 2015-12-02 2018-07-23 아게누스 인코포레이티드 Antibodies and methods for their use
SG11201805422WA (en) 2016-01-11 2018-07-30 Inhibrx Inc Multivalent and multispecific ox40-binding fusion proteins
DE102016105069A1 (en) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antiviral immunotherapy by membrane receptor ligation
US20190263918A1 (en) * 2016-06-08 2019-08-29 Shanghai Jiao Tong University School Of Medicine Sequence of antibody heavy chain constant region for enhancing agonistic antibody activity
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018031258A1 (en) * 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
CN109843916B (en) * 2016-08-12 2023-10-31 詹森生物科技公司 Fc-engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof
TWI788307B (en) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
CA3041988A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
TWI734879B (en) * 2016-12-15 2021-08-01 美商艾伯維生物醫療股份有限公司 Anti-ox40 antibodies and their uses
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
TW201837168A (en) 2017-01-06 2018-10-16 美商艾歐凡斯生物治療公司 Expansion of tumor infiltrating lymphocytes (TILS) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILS and TNFRSF agonists
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for the depletion of cd137plus cells
SG11201906961UA (en) 2017-02-10 2019-08-27 Genmab Bv Polypeptide variants and uses thereof
CN108623686A (en) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 Anti- OX40 antibody and application thereof
CN113480655B (en) * 2017-03-28 2022-05-31 礼进生物医药科技（上海）有限公司 Therapeutic agents and methods for enhancing immune response in tumor microenvironment
WO2018226714A1 (en) 2017-06-05 2018-12-13 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
JP7089149B2 (en) 2017-07-31 2022-06-22 ミツミ電機株式会社 Lens drive, camera module, and camera-mounted device
CA3074317A1 (en) * 2017-08-25 2019-02-28 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
JP2021501801A (en) 2017-11-01 2021-01-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Immunostimulatory agonist antibody for use in the treatment of cancer
BR112020009663A2 (en) 2017-11-17 2020-11-10 Iovance Biotherapeutics, Inc. method for the expansion of tumor infiltrating lymphocytes (tils) in a therapeutic population of tils, method for the treatment of an individual with cancer, composition
KR20240023192A (en) * 2017-11-24 2024-02-20 유큐(베이징) 바이오파마 코., 엘티디 Anti-OX40 Antibodies and Uses Thereof
JP7057492B2 (en) 2017-12-28 2022-04-20 ミツミ電機株式会社 Lens drive device, camera module, and camera mount device
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2019136456A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN110092832B (en) * 2018-01-29 2020-03-31 康源博创生物科技(北京)有限公司 anti-OX 40 antibodies and uses thereof
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CN111886256A (en) 2018-03-23 2020-11-03 百时美施贵宝公司 anti-MICA and/or MICB antibodies and uses thereof
KR20200136454A (en) 2018-03-27 2020-12-07 브리스톨-마이어스 스큅 컴퍼니 Real-time monitoring of protein concentration using ultraviolet signals
KR20210005138A (en) 2018-04-27 2021-01-13 이오반스 바이오테라퓨틱스, 인크. Closure method for expansion and gene editing of tumor infiltrating lymphocytes and their use in immunotherapy
EP4074732A1 (en) 2018-05-11 2022-10-19 Wuxi Biologics (Shanghai) Co. Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
CA3100766A1 (en) * 2018-05-23 2019-11-28 Beigene, Ltd. Anti-ox40 antibodies and methods of use
MA52889A (en) 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc INCREASED IMMUNE ACTIVITY BY MODULATION OF POST-CELLULAR SIGNALING FACTORS
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
WO2020036867A1 (en) 2018-08-13 2020-02-20 Inhibrx, Inc. Ox40-binding polypeptides and uses thereof
TW202031273A (en) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 Treatment of nsclc patients refractory for anti-pd-1 antibody
JP2022501038A (en) 2018-09-20 2022-01-06 アイオバンス バイオセラピューティクス，インコーポレイテッド Expanded culture of TIL from cryopreserved tumor samples
WO2020096989A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
EP3877512A2 (en) 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CN113272421A (en) 2018-11-05 2021-08-17 艾欧凡斯生物治疗公司 Method for generating tumor infiltrating lymphocytes and use thereof in immunotherapy
MX2021004775A (en) 2018-11-05 2021-06-08 Iovance Biotherapeutics Inc Expansion of tils utilizing akt pathway inhibitors.
WO2020119793A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Humanized antibodies against ox40, method for preparing the same, and use thereof
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020142626A1 (en) * 2019-01-04 2020-07-09 Gigagen, Inc. Anti-ox40 binding proteins and methods of use thereof
US20220135619A1 (en) 2019-02-24 2022-05-05 Bristol-Myers Squibb Company Methods of isolating a protein
CN114269370A (en) 2019-03-29 2022-04-01 迈斯特治疗公司 Methods of ex vivo production of T cell therapeutics and related compositions and methods
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN114245869A (en) 2019-05-23 2022-03-25 百时美施贵宝公司 Method for monitoring cell culture medium
KR20220016157A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Cell localization signatures and combination therapies
CN114127315A (en) 2019-05-30 2022-03-01 百时美施贵宝公司 Method of identifying subjects suitable for immunooncology (I-O) therapy
JP2022534967A (en) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー Multiple tumor gene signatures and their uses
CN110172090B (en) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 CD134 monoclonal antibody, preparation method thereof and application thereof in cancer treatment
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023504042A (en) 2019-11-27 2023-02-01 ミスト セラピューティクス リミテッド ライアビリティ カンパニー Methods of generating tumor-reactive T-cell compositions using modulators
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL293471A (en) 2019-12-17 2022-08-01 Amgen Inc Dual interleukin-2 /tnf receptor agonist for use in therapy
CN113045655A (en) * 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 anti-OX 40 antibodies and uses thereof
CN115427438A (en) 2020-02-27 2022-12-02 迈斯特治疗公司 Methods for ex vivo enrichment and expansion of tumor-reactive T cells and compositions related thereto
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
TW202208617A (en) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN111518209B (en) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 Monoclonal antibodies that specifically bind to human OX40 and uses thereof
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022076318A1 (en) 2020-10-05 2022-04-14 Bristol-Myers Squibb Company Methods for concentrating proteins
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (en) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of NSCLC patients with tumor-infiltrating lymphocyte therapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501452A (en) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer patients with tumor-infiltrating lymphocyte therapy in combination with BRAF inhibitors and/or MEK inhibitors
WO2022133140A1 (en) 2020-12-17 2022-06-23 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
JP2024500403A (en) 2020-12-17 2024-01-09 アイオバンス バイオセラピューティクス，インコーポレイテッド Treatment of cancer with tumor-infiltrating lymphocytes
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
JP2024505600A (en) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド Binders and how to use them
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
JP2024514530A (en) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Antibodies against truncated CDCP1 and uses thereof
JP2024515189A (en) 2021-04-19 2024-04-05 アイオバンス バイオセラピューティクス，インコーポレイテッド Chimeric costimulatory receptors, chemokine receptors, and their uses in cellular immunotherapy - Patents.com
KR20220160512A (en) * 2021-05-27 2022-12-06 주식회사유한양행 Ox40 agonist and use thereof
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023009716A1 (en) 2021-07-28 2023-02-02 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AR127482A1 (en) 2021-10-27 2024-01-31 Iovance Biotherapeutics Inc SYSTEMS AND METHODS TO COORDINATE THE MANUFACTURE OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023147486A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE275198T1 (en) 1991-12-02 2004-09-15 Medical Res Council PRODUCTION OF ANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES.
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (en) 1993-04-29 2002-01-16 Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5591629A (en) 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5504004A (en) 1994-12-20 1996-04-02 Michigan Biotechnology Institute Process for making succinic acid, microorganisms for use in the process and methods of obtaining the microorganisms
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1029048A2 (en) 1997-11-05 2000-08-23 Baylor College Of Medicine Sequences for targeting metastatic cells
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
ATE477280T1 (en) 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
SI1517921T1 (en) 2002-06-28 2006-10-31 Domantis Ltd Dual specific ligands with increased serum half-life
WO2004111233A1 (en) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha Process for producing antibody
US20080287309A1 (en) 2004-07-10 2008-11-20 Alexion Pharmaceuticals, Inc. Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California Combination cancer immunotherapy with co-stimulatory molecules
US20060153808A1 (en) 2004-11-17 2006-07-13 Board Of Regents, The Universtiy Of Texas System Cancer immunotherapy incorporating p53
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
KR101374454B1 (en) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 Methods for producing polypeptides by regulating polypeptide association
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP1896030A1 (en) 2005-06-03 2008-03-12 Pfizer Products Incorporated Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
JP5525729B2 (en) 2005-11-28 2014-06-18 ゲンマブ エー／エス Recombinant monovalent antibody and production method thereof
US20070255631A1 (en) 2005-11-28 2007-11-01 Douglas Schmidt Product catalog management system and method
AU2007229698B9 (en) 2006-03-24 2012-11-08 Merck Patent Gmbh Engineered heterodimeric protein domains
EP2038303A2 (en) 2006-06-21 2009-03-25 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
JP2010518873A (en) 2007-02-27 2010-06-03 ジェネンテック， インコーポレイテッド Antagonist anti-OX40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
ES2593484T3 (en) 2007-03-29 2016-12-09 Genmab A/S Bispecific antibodies and their production methods
CN101293924A (en) * 2007-04-24 2008-10-29 上海国健生物技术研究院 Monoclone antibody with combined function epiposition, specificity of osteopontin and in preparing antineoplastic diversion medicaments
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
SG10201604770VA (en) 2007-12-14 2016-08-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
JP2011507519A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
CA2709847C (en) 2008-01-07 2018-07-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
US8137933B2 (en) 2008-11-12 2012-03-20 Schering Corporation Mammalian expression vector pUHAB
MX2011008697A (en) 2009-02-17 2011-11-18 Ucb Pharma Sa Antibody molecules having specificity for human ox40.
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
KR20170080705A (en) * 2009-05-08 2017-07-10 백시넥스 인코포레이티드 Anti-cd100 antibodies and methods for using the same
CA2785969A1 (en) 2009-09-08 2011-03-17 Aerovironment, Inc. Electric vehicle simulator and analyzer (evsa) for electric vehicle supply equipment
EP3141260B1 (en) 2009-11-30 2019-08-14 Janssen Biotech, Inc. Antibody fc mutants with ablated effector functions
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CA2797981C (en) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
ES2649155T3 (en) * 2010-08-23 2018-01-10 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and procedures for their use
DK2635607T3 (en) 2010-11-05 2019-11-18 Zymeworks Inc STABLE HETERODIMED ANTIBODY DESIGN WITH MUTATIONS IN THE FC DOMAIN
JP5925307B2 (en) 2011-06-30 2016-05-25 オーエフエス ファイテル，エルエルシー Fiber stretcher module for use in the 1550 nm wavelength range
PT2731677T (en) * 2011-07-11 2018-07-27 Glenmark Pharmaceuticals Sa Antibodies that bind to ox40 and their uses
EP2748199B1 (en) * 2011-08-23 2019-08-28 Board of Regents, The University of Texas System Anti-ox40 antibodies and methods of using the same
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (en) 2011-11-11 2016-08-10 Юсб Фарма С.А. Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin
BR112015023862A2 (en) 2013-03-18 2017-10-24 Biocerox Prod Bv isolated antibody, isolated nucleic acid molecule, vector, host cell, method of enhancing an immune response, method of treating cancer, pharmaceutical composition, and isolated agonistic antibody
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
MA51552A (en) 2014-03-31 2021-03-24 Hoffmann La Roche ANTI-OX40 ANTIBODIES AND METHODS OF USE
RU2016142476A (en) 2014-03-31 2018-05-07 Дженентек, Инк. COMBINED THERAPY, INCLUDING ANTI-ANGIOGENESIS AGENTS AND AGONISTS BINDING OX40
TW201619200A (en) 2014-10-10 2016-06-01 麥迪紐有限責任公司 Humanized anti-OX40 antibodies and uses thereof
CN107109484B (en) 2014-11-03 2021-12-14 豪夫迈·罗氏有限公司 Methods and biomarkers for efficacy prediction and assessment of OX40 agonist treatment
CN106796235B (en) 2014-11-03 2021-01-29 豪夫迈·罗氏有限公司 Assays for detecting T cell immune subsets and methods of use thereof
CN107073126A (en) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 Combination treatment comprising OX40 combinations activator and TIGIT inhibitor
BR112017010198A2 (en) 2014-11-17 2017-12-26 Genentech Inc combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
MX2017012805A (en) 2015-04-07 2018-04-11 Genentech Inc Antigen binding complex having agonistic activity and methods of use.
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
WO2018031258A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions

Also Published As

Publication number Publication date
CY1120752T1 (en) 2019-12-11
AU2014238546B2 (en) 2018-10-18
CR20150498A (en) 2016-03-30
HUE040234T2 (en) 2019-02-28
EP2976361B1 (en) 2018-07-18
KR20160006168A (en) 2016-01-18
DK2976361T3 (en) 2018-10-01
US20170369586A1 (en) 2017-12-28
PL2976361T3 (en) 2018-12-31
BR112015023862A2 (en) 2017-10-24
NZ712903A (en) 2018-07-27
LT2976361T (en) 2018-10-25
US20190202928A1 (en) 2019-07-04
EP2976361A1 (en) 2016-01-27
US9790281B2 (en) 2017-10-17
IL241701A0 (en) 2015-11-30
CA2907436A1 (en) 2014-09-25
PH12015502185A1 (en) 2016-01-25
CN105229032A (en) 2016-01-06
SI2976361T1 (en) 2018-11-30
EA201591495A1 (en) 2016-05-31
CL2015002793A1 (en) 2016-09-23
ZA201507021B (en) 2016-11-30
AU2014238546C1 (en) 2019-01-17
PE20160690A1 (en) 2016-08-14
EP3409690A1 (en) 2018-12-05
MD20150102A2 (en) 2016-02-29
WO2014148895A1 (en) 2014-09-25
MX2015013288A (en) 2016-04-07
JP2016515544A (en) 2016-05-30
MX2019004649A (en) 2019-08-05
HRP20181478T1 (en) 2018-11-02
ES2687282T3 (en) 2018-10-24
US10273307B2 (en) 2019-04-30
MD4633B1 (en) 2019-06-30
SG11201507781VA (en) 2015-10-29
HK1215035A1 (en) 2016-08-12
RS57840B1 (en) 2018-12-31
UA119319C2 (en) 2019-06-10
AU2019200164A1 (en) 2019-01-31
MD20180107A2 (en) 2019-06-30
CL2018003807A1 (en) 2019-03-08
US20140377284A1 (en) 2014-12-25
AU2014238546A1 (en) 2015-10-01
PT2976361T (en) 2018-10-19

Similar Documents

Publication Publication Date Title
HRP20181478T1 (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
IL261743B (en) Anti-il-33 antibodies and uses thereof
IL261547B (en) Anti-hepcidin antibodies and uses thereof
IL245040A0 (en) Anti-pdgfr-beta antibodies and uses thereof
HK1220206A1 (en) Anti-prlr antibodies and uses thereof prlr
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
EP2970505A4 (en) Bispecific antibodies and uses thereof
HK1216893A1 (en) Anti-tweakr antibodies and uses thereof tweakr
PT3026062T (en) Anti-pd-1 antibody and use thereof
EP3066470A4 (en) Humanized anti-ceacam5 antibody and uses thereof
HK1223950A1 (en) Monoclonal olfml-3 antibodies and uses thereof olfml-3